A clinical review in Mayo Clinic Proceedings notes that GI effects are common across GLP-1 and related therapies
Kai Uwe Lewandowski, a Professor of Surgery at the University of Arizona School of Medicine and co-author of the paper, concluded: "Depression was the most commonly reported adverse event associated with these drugs, followed by anxiety and suicidal ideation
Weight reduction was 9.6% with semaglutide versus 3.4% with placebo
Notify your doctor if you have myasthenia gravis (may worsen muscle weakness) or other neuromuscular disorders, severe dehydration, or electrolyte abnormalities, as these can increase risk of side effects
The second user also follows the same plan length as the primary, so if one person signs up for six months, the other is along for the same timeline
When GLP-1R is stimulated, various downstream signaling pathways become activated, including cAMP/PKA, cAMP/Epac/PI3K/Akt, and ERK/MAPK